Efavirenz
Back to searchMolecule Structure
Scientific Name
Efavirenz
Description of the Drug
Efavirenz is a non-nucleoside reverse transcriptase inhibitor used to treat HIV infection or prevent the spread of HIV.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00625
http://www.drugbank.ca/drugs/DB00625
Brand Name(s)
Efavirenz, Sustiva, Sustiva 600
Company Owner(s)
Cipla Ltd, Bristol Myers Squibb Co, Mylan Laboratories Ltd, Macleods Pharmaceuticals Ltd, Laurus Labs Ltd, Hetero Labs Ltd Unit Iii, Aurobindo Pharma Ltd, Hetero Labs Ltd Unit V, Gilead Sciences Llc, Mylan Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Human immunodeficiency virus type 1 reverse transcriptase | SINGLE PROTEIN | INHIBITOR | CHEMBL247 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL37762 | |
| PharmGKB | PA449441 | |
| Human Metabolome Database | HMDB0014763 | |
| DrugBank | DB00625 | |
| PubChem: Thomson Pharma | 14850291 | |
| PubChem | 64139 | |
| Mcule | MCULE-3949811498 | |
| LINCS | LSM-5526 | |
| Nikkaji | J727.577C | |
| PDBe | EFZ | |
| BindingDB | 2483 | |
| EPA CompTox Dashboard | DTXSID9046029 | |
| DrugCentral | 989 | |
| Brenda | 1704 | 42381 |
| ChemicalBook | CB7181559 | |
| Guide to Pharmacology | 11287 | |
| rxnorm | EFAVIRENZ | SUSTIVA |
| PubChem: Drugs of the Future | 12014858 | |
| KEGG Ligand | C08088 | |
| ChEBI | 119486 | |
| ZINC | ZINC000002020233 |
